Format

Send to

Choose Destination
Am J Cancer Res. 2016 Nov 1;6(11):2575-2586. eCollection 2016.

MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.

Author information

1
Department of General Surgery, Tangdu Hospital, The Fourth Military Medical University Xi'an 710032, Shaanxi, China.
2
Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University Xi'an 710032, Shaanxi, China.
3
Department of Pathology, Tangdu Hospital, The Fourth Military Medical University Xi'an 710032, Shaanxi, China.
4
Department of Anesthesiology, PLA Army General Hospital Beijing 100700, China.
5
Department of Neurosurgery, 451th Central Hospital of PLA Xi'an 710054, Shaanxi, China.
6
Department of Dermatology, Tangdu Hospital, The Fourth Military Medical University Xi'an 710032, Shaanxi, China.

Abstract

Increasing evidence suggests that microRNA-101 (miR-101) is involved in the progression of various human cancers, including papillary thyroid carcinoma (PTC). However, the biological functions of miR-101 and underlying molecular mechanisms in PTC remain largely unknown. In this study, we demonstrated that miR-101 underexpression in PTC tissue was associated with lymph node metastasis and poor prognosis of PTC patients. MiR-101 reduced PTC cell proliferation, apoptosis resistance, and invasion. Ubiquitin-specific protease 22 (USP22) was confirmed as a direct target of miR-101. USP22 restoration attenuated the inhibitory effects of miR-101 on PTC malignant traits in vitro. In vivo, miR-101 overexpression or USP22 depletion reduced the tumorigenesis of PTC. Overall, our findings provide new insight into the mechanism of PTC inhibition by miR-101, suggesting the potential of miR-101 as a therapeutic target in PTC patients.

KEYWORDS:

MicroRNA-101; papillary thyroid carcinoma; tumorigenesis; ubiquitin-specific protease 22

PMID:
27904772
PMCID:
PMC5126274

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center